On Apr. 2, 2020, Amgen and Adaptive Biotechnologies announced a collaboration aimed at helping address the COVID-19 pandemic. The mutually exclusive collaboration brings together Adaptiveﾒs proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgenﾒs expertise in immunology and novel antibody therapy development.